CRISPR/Cas9 screening platform have been used to identify genetic vulnerabilities in acute myeloid leukemia (AML) cells, including several established (such as DOT1L, BCL2, and MEN1) and novel (such as KAT2A) therapeutic targets for AML [88]. The gene discussed is MEN1; the disease is acute myeloid leukemia.